Product Description
ISM6331 is a potent non-covalent small molecule inhibitor with a novel scaffold targeting the transcriptional enhanced associate domain (TEAD) protein family, which are considered to be key regulators of the Hippo pathway, and play an important role in tumor progression, metastasis, cancer metabolism, immunity and drug resistance. Insilico Medicine received IND approval and orphan drug designation from FDA for ISM6331, an AI-designed TEAD inhibitor targeting solid tumors and mesothelioma. (Sourced from: https://www.eurekalert.org/news-releases/1053820)
Mechanisms of Action: TEAD Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InSilico Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|